"A new analysis of data from 20 major U.S. cities reveals continued signs of sexual risk among gay and bisexual men, but shows dramatically lower sexual risk among those who accurately know their HIV status. The findings were published today in CD"...
DOSAGE AND ADMINISTRATION
VIDEX should be administered on an empty stomach, at least 30 minutes before or 2 hours after eating.
Recommended Dosage (Adult and Pediatric Patients)
The preferred dosing frequency of VIDEX is twice daily because there is more evidence to support the effectiveness of this dosing regimen. Once-daily dosing should be considered only for patients whose management requires once-daily dosing of VIDEX [see Clinical Studies]. The recommended adult total daily dose is based on body weight (kg) (see Table 1).
Table 1: Recommended Dosage (Adult)
|at least 60 kg||less than 60 kg|
|Preferred dosing||200 mg twice daily||125 mg twice daily|
|Dosing for patients whose management requires once-daily frequency||400 mg once daily||250 mg once daily|
Pediatric Patients (2 weeks old to 18 years old): The recommended dose of VIDEX (didanosine) in pediatric patients between 2 weeks old and 8 months old is 100 mg/m² twice daily, and the recommended VIDEX dose for pediatric patients greater than 8 months old is 120 mg/m² twice daily but not to exceed the adult dosing recommendation.
Dosing recommendations in patients less than 2 weeks of age cannot be made because the pharmacokinetics of didanosine in these children are too variable to determine an appropriate dose. There are no data on once-daily dosing of VIDEX in pediatric patients.
In adult patients with impaired renal function, the dose of VIDEX should be adjusted to compensate for the slower rate of elimination. The recommended doses and dosing intervals of VIDEX in adult patients with renal insufficiency are presented in Table 2.
Table 2: Recommended Dosage in Patients with Renal Impairment
|Creatinine Clearance (mL/min)||Recommended VIDEX Dose by Patient Weight|
|at least 60 kg||less than 60 kg|
|at least 60||200 mg twice dailya||125 mg twice dailya|
|30-59||200 mg once daily
or 100 mg twice daily
|150 mg once daily
or 75 mg twice daily
|10-29||150 mg once daily||100 mg once daily|
|less than 10||100 mg once daily||75 mg once daily|
|a 400 mg once daily (at least 60 kg) or 250 mg once daily (less than 60 kg) for patients whose management requires once-daily frequency of administration.|
Urinary excretion is also a major route of elimination of didanosine in pediatric patients, therefore the clearance of didanosine may be altered in pediatric patients with renal impairment. Although there are insufficient data to recommend a specific dose adjustment of VIDEX in this patient population, a reduction in the dose should be considered (see Table 2).
Patients Requiring Continuous Ambulatory Peritoneal Dialysis (CAPD) or Hemodialysis
For patients requiring CAPD or hemodialysis, follow dosing recommendations for patients with creatinine clearance of less than 10 mL/min, shown in Table 2. It is not necessary to administer a supplemental dose of VIDEX following hemodialysis.
Concomitant Therapy with Tenofovir Disoproxil Fumarate
In patients who are also taking tenofovir disoproxil fumarate, a dose reduction of VIDEX to 250 mg (adults weighing at least 60 kg with creatinine clearance of at least 60 mL/min) or 200 mg (adults weighing less than 60 kg with creatinine clearance of at least 60 mL/min) once daily is recommended. VIDEX and tenofovir disoproxil fumarate may be taken together in the fasted state. Alternatively, if tenofovir disoproxil fumarate is taken with food, VIDEX should be taken on an empty stomach (at least 30 minutes before food or 2 hours after food). The appropriate dose of VIDEX coadministered with tenofovir disoproxil fumarate in patients with creatinine clearance of less than 60 mL/min has not been established. ([See DRUG INTERACTIONS and CLINICAL PHARMACOLOGY]; see the complete prescribing information for VIDEX EC (enteric-coated formulation of didanosine) for results of drug interaction studies of tenofovir disoproxil fumarate with reduced doses of the enteric-coated formulation of didanosine.)
Dosage Forms And Strengths
VIDEX (didanosine, USP) Pediatric Powder for Oral Solution is supplied in 4- and 8-ounce glass bottles containing 2 g or 4 g of VIDEX, respectively.
Storage And Handling
VIDEX (didanosine, USP) Pediatric Powder for Oral Solution is supplied as shown in Table 15:
Table 15: VIDEX Pediatric Powder for Oral Solution
|NDC NO.||Packaging Information||Product Quantity|
|0087-6632-41||One, 4-ounce glass, bottle per carton||2 g/bottle|
|0087-6633-41||One, 8-ounce glass, bottle per carton||4 g/bottle|
Prior to dispensing, the pharmacist must reconstitute dry powder with Purified Water, USP, to an initial concentration of 20 mg/mL and immediately mix the resulting solution with antacid to a final concentration of 10 mg/mL as follows:
20 mg/mL Initial Solution
Reconstitute the product to 20 mg/mL by adding 100 mL or 200 mL of Purified Water, USP, to the 2 g or 4 g of VIDEX powder, respectively, in the product bottle.
10 mg/mL Final Admixture
- Immediately mix one part of the 20 mg/mL initial solution with one part of Maximum Strength Mylanta® Liquid for a final dispensing concentration of 10 mg VIDEX per mL. For patient home use, the admixture should be dispensed in appropriately sized, flint-glass or plastic (HDPE, PET, or PETG) bottles with child-resistant closures.
- Instruct the patient to shake the admixture thoroughly prior to use and to store the tightly closed container in the refrigerator.
The bottles of powder should be stored at 59° F to 86° F (15° C to 30° C). The VIDEX admixture may be stored up to 30 days in a refrigerator, 36° F to 46° F (2° C to 8° C). Discard any unused portion after 30 days.
Bristol-Myers Squibb Company Princeton, NJ 08543 USA. Revised: November 2011
Last reviewed on RxList: 12/6/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Videx Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.